Delivery Order SPE2DB24D2101-SPE2DB24FKFBF

Award Date 7/8/24
Potential Completion Date 7/9/24
Potential Value $27K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Contrave ER 8-90 mg tablets in quantities of 120. The contract has a firm fixed price of $11,258.41 and a completion date of February 21, 2024. This contract is a delivery order, not associated with a larger vehicle. There was no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Contrave ER 8-90 mg tablets. The firm-fixed-price, $2,970.63 delivery order contract has an ultimate completion date of December 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of the drug Contrave ER 8-90 mg tablets. The delivery order, valued at $5,367.46, is a firm-fixed-price contract with an ultimate completion date of October 24, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Contrave ER 8-90 mg tablets. The fixed-price delivery order, valued at $3,871.70, has a performance period through May 14, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to deliver Contrave ER 8-90 mg tablets. The $9,288.39 firm fixed-price delivery order is a part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026. The IDC enables the government to efficiently procure a wide range of pharmaceutical products and medical supplies to support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Contrave ER 8-90 mg tablets. The $12,031.15 firm fixed price contract has a performance period through July 15, 2024 and is not associated with a set-aside requirement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,770.94 firm fixed-price delivery order contract is for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of May 31, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $21,096.90 with a period of performance through May 2, 2024. The contract is for the supply of Contrave ER 8-90 MG Tablet, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,189.76 delivery order contract is for the supply of the prescription medication Contrave ER 8-90 mg tablets. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,196.27 Firm Fixed Price delivery order is for the supply of Contrave ER 8-90 mg tablets. The contract has a period of performance through September 16, 2024 and was awarded on September 13, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen...
  • SPE2DB24D2101
    Indefinite Delivery Contract
  • SPE2DB24D2101-SPE2DB24FKFBF
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,007.04, is for the delivery of the drug Contrave ER 8-90 mg tablets.

The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 10:10 AM